Upcoming events on ELI LILLY AND COMPANY |
|
01/29/21 | | Esercizio 2020 Pubblicazione dei risultati |
01/29/21 | 03:00pm | | Esercizio 2020 Presentazione dei risultati |
02/11/21 | | Desprendimiento de dividendo |
04/27/21 | 03:00pm | | Q1 2021 Presentazione dei risultati |
|
Past events on ELI LILLY AND COMPANY |
|
01/12/21 | 02:20pm | | JP Morgan Healthcare Conference |
12/15/20 | 02:30pm | | Esercizio 2021 Previsioni della società |
12/09/20 | | San Antonio Breast Cancer Symposium |
12/01/20 | 08:40pm | | Evercore ISI HealthCONx Conference |
|
Upcoming sector events for ELI LILLY AND COMPANY |
|
|
|
Past sector events for ELI LILLY AND COMPANY |
|
|
|
Annual results | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 (e) |
Sales M $ |
Released Forecast Spread | 19 959 19 904 0,27% | 21 222 20 992 1,1% | 22 871 22 638 1,0% | 24 556 24 404 0,62% | 22 320 22 142 0,80% | 24 415
|
Operating income (EBITDA) M $ |
Released Forecast Spread | 5 799 5 617 3,2% | 5 368 5 549 -3,3% | 6 541 6 474 1,0% | 7 829 7 943 -1,4% | 7 551 7 508 0,57% | 8 713
|
Operating profit (EBIT) M $ |
Released Forecast Spread | 4 371 4 448 -1,7% | 4 555 4 668 -2,4% | 5 649 5 617 0,57% | 6 766 6 743 0,34% | 6 079 6 106 -0,44% | 7 529
|
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread | 2 790 3 431 -19% | 3 374 3 647 -7,5% | 2 197 2 230 -1,5% | 3 796 3 930 -3,4% | 5 266 8 975 -41% | 7 041
|
Net income M $ |
Released Forecast Spread | 2 408 2 632 -8,5% | 2 738 2 806 -2,5% | -204 1 756 -112% | 3 232 3 281 -1,5% | 8 318 8 090 2,8% | 5 821
|
EPS $ |
Released Forecast Spread | 2,26 2,44 -7,2% | 2,58 2,63 -1,9% | -0,19 1,65 -111% | 3,13 3,14 -0,18% | 8,89 8,65 2,8% | 6,38
| Announcement Date | 01/28/2016 | 01/31/2017 | 01/31/2018 | 02/06/2019 | 01/30/2020 | |
|
|
Quarterly results | 2018 Q2 | 2018 Q3 | 2018 Q4 | 2019 Q1 | 2019 Q2 | 2019 Q3 | 2019 Q4 | 2020 Q1 | 2020 Q2 | 2020 Q3 | 2020 Q4 (e) | 2021 Q1 (e) | 2021 Q2 (e) | 2021 Q3 (e) | 2021 Q4 (e) |
Sales M $ |
Released Forecast Spread | 6 355 6 050 5,0% | 6 062 6 044 0,30% | 6 439 6 280 2,5% | 5 092 5 116 -0,46% | 5 637 5 589 0,85% | 5 477 5 496 -0,35% | 6 114 5 923 3,2% | 5 860 5 481 6,9% | 5 499 5 769 -4,7% | 5 741 5 867 -2,1% | 7 270
| 6 670
| 6 789
| 6 700
| 7 232
|
Operating income (EBITDA) M $ |
Released Forecast Spread | 2 125 1 909 11% |
| 1 875
| 1 691 1 713 -1,3% |
|
|
| 2 036 2 024 0,58% | 1 865 2 100 -11% | 1 865 2 539 -27% | 3 221
|
|
|
|
|
Operating profit (EBIT) M $ |
Released Forecast Spread | 1 852 1 617 15% | 1 692 1 657 2,1% | 1 617 1 613 0,23% | 1 334 1 486 -10% | 1 575 1 631 -3,5% | 1 565 1 590 -1,6% | 1 605 1 694 -5,2% | 1 762 1 598 10% | 1 541 1 764 -13% | 1 506 1 832 -18% | 2 588
| 2 005
| 2 152
| 2 212
| 2 468
|
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread | 4,80 1 460 -100% | 1 411 1 478 -4,5% | 939
| 731 1 140 -36% |
|
|
|
|
|
|
|
|
|
|
|
Net income M $ |
Released Forecast Spread | -260 947 -127% | 1 150 1 207 -4,8% | 1 125 1 215 -7,4% | 4 242 906 368% | 1 327 1 306 1,7% | 1 254 1 273 -1,5% | 1 496 1 456 2,7% | 1 457 1 206 21% | 1 412 1 395 1,2% | 1 208 1 447 -17% | 1 995
|
|
|
|
|
EPS $ |
Released Forecast Spread | -0,25 0,90 -128% | 1,12 1,17 -4,3% | 1,10 1,19 -7,2% | 4,31 0,95 354% | 1,44 1,41 2,1% | 1,37 1,38 -0,76% | 1,64 1,54 6,3% | 1,60 1,35 18% | 1,55 1,53 1,6% | 1,33 1,61 -18% | 2,06
|
|
|
|
| Announcement Date | 07/24/2018 | 11/06/2018 | 02/06/2019 | 04/30/2019 | 07/30/2019 | 10/23/2019 | 01/30/2020 | 04/23/2020 | 07/30/2020 | 10/27/2020 | | | | | |
|
Financial data source © 2021 S&P Global Market Intelligence
|
|
© 2021 Factset
|
|
|
|
Eli Lilly to buy gene therapy developer Prevail in about $1 bln deal |
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise
|